Clinical Trials Browser

Completed × Pheochromocytoma × NET × Clear all

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

200 enrolled

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Phase 1/2 Completed

24 enrolled 8 charts

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00339131 2011-10-12

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Phase 1 Completed

24 enrolled

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Clinical Trials

CABATEN

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid